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Abstract
Background: Medication overuse headache (MOH) is a major clinical concern and a common health risk. Recent
literature stressed the need to manage chronic headache by using integrated biobehavioral approaches. Few
studies evaluated how biofeedback can be useful in MOH.
The aim of the study is to evaluate in a randomized, controlled, single-blind trial the effects of biofeedback
associated with traditional pharmacological therapy in the prophylactic treatment of MOH.
Method: Twenty-seven subjects were randomized to frontal electromyographic (EMG) biofeedback associated with
prophylactic pharmacological therapy (Bfb Group) or to pharmacological treatment alone (Control Group). The primary
outcome was to evaluate the number of patients that return episodic after treatment. Secondly we evaluate the effects
of frontal EMG BFB on frequency of headache and analgesic intake. Changes in coping strategies and in EMG frontalis
tension were also evaluated. ANOVA was performed on all the variables of interest.
Results: Our results indicate that at the end of treatment the number of patients that returned episodic in the Bfb
group was significantly higher than in the Control group. Patients in the Bfb group differed from the Control group in
headache frequency, amount of drug intake and active coping with pain. These outcomes were confirmed also after
4 months of follow-up. No significant effects were observed in EMG recordings.
Conclusions: Biofeedback added to traditional pharmacological therapy in the treatment of MOH is a promising
approach for reducing headache frequency and analgesic intake. Modification of coping cognitions in the Bfb group,
as an adjunct mechanism of self-regulation, needs more evaluations to understand the role of biofeedback in
changing maladaptive psychophysiological responses.
Keywords: Biofeedback, Coping strategies, Psychological treatment, Chronic migraine, Medication overuse headache,
Preventive therapy
Background
Chronic headache comprise individuals with chronic
tension-type headache (CTTH) and chronic migraine
(CM), both of which may be associated with medication
overuse and medication overuse headache (MOH) [1].
In particular, MOH is a major clinical concern and a
common health risk [2]. It has a prevalence of about 1–
2 % in the general population [3]. The International
Classification of Headache Disorders 3rd edition (beta
version) suggests a double diagnosis of either CM or
CTTH and MOH, since MOH is excluded or confirmed
by analgesic withdrawal.
The treatment of MOH is often complex and includes
patient education, discontinuation of the offending
drug, rescue therapy for withdrawal symptoms, and
preventive therapy [4]. In particular, the withdrawal of
the overused medication is recognized as the treatment
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of choice [5–10]. Such a treatment is often compro-
mised by lack of motivation and poor patient’s self-
awareness [11].
In the literature [12–14] the basic psychological factors
that are key contributors to MOH are described as fol-
lows: a belief that acute medication is the only treatment
option, the presence of cephalalgiaphobia [12] (or pain
panic, i.e. anticipatory fear of pain), intolerance or diffi-
culty dealing with pain, soporophilia (seeking sedation),
the need to maintain the usual daily activities, presence
of outside pressures and of psychiatric comorbidities.
Chronic headaches should be treated with multidi-
mensional approaches that can support patients not only
pharmacologically but also giving them behavioral and
cognitive strategies to cope with their pain [15]. One of
the non-pharmacological treatments that has shown
positive results in treating migraine and tension-type
headache is biofeedback [16–20]. Electromyographic
biofeedback (EMG BFB) has proved to be effective in
reducing pain symptoms associated with both tension-
type headache and migraine [17, 19]. Moreover, it has
been shown that many forms of headache, especially if
chronic, eventually end up in a mixed headache type,
and may meet the criteria for TTH [21, 22]. Although
there is a large amount of scientific evidence on biobe-
havioral therapies for headache [23], few studies evalu-
ated how psychological treatments could be integrated
with pharmacological prophylaxis in order to favor the
reduction of acute medication intake [18, 21]. Only one
study [24] evaluated the effects of EMG BFB in a com-
bined treatment of transformed migraine with analgesic
overuse. Data showed that patients treated with biofeed-
back and pharmacological therapy, after analgesic with-
drawal, improved in headache frequency and analgesic
intake similarly to control group, but have better
improvement after 3 years of follow-up..
No data are available about the role that biofeedback
treatment could have in reducing medication overuse
without a structured drug withdrawal. Moreover, it has
not yet been investigated if biofeedback, as an active
self-regulation intervention, could also help MOH pa-
tients by changing their strategies to cope with headache
attacks in comparison with pharmacological treatment.
Indeed, the role of coping strategies in managing
chronic pain and headache has been previously investi-
gated [25–29]. In particular, some studies explored the
role of pain catastrophizing (as a maladaptive coping
strategy) in migraine. Catastophizing is associated with
impaired quality of life [26], chronicity of headache and
poorer treatment response [27, 28]; whereas few studies
analyzed the effects of biofeedback treatment on coping
skills [16].
In his meta-analysis on efficacy of BFB on migraine,
Nestoriuc found that self-efficacy yielded higher effect
sizes than the actual pain related outcome measures of
biofeedback and recommended studies to directly inves-
tigate whether changes in self-efficacy (and subsequent
changes in coping strategies) mediate the treatment
effects of BFB. Currently, no data are available on modi-
fications in coping skills after biofeedback training in
MOH.
The aims of the present study were to evaluate the
effects of EMG BFB associated with traditional pharma-
cological interventions on patients with MOH without
previous withdrawal intervention in a tertiary headache
center. The primary outcome was to evaluate the num-
ber of patients that return episodic after treatment.
Secondly we evaluate the effects of frontal EMG BFB on
frequency of headache and analgesic intake. Changes in
coping strategies and in EMG frontalis tension were also
evaluated.
Method
Participants
All consecutive patients attending the Headache Center
of IRCCS Institute of Neurological Sciences of Bologna
in a range of 2 years (from 2008 to 2010), satisfying in-
clusion criteria for CM and MOH or CTTH and MOH,
and accepting to participate were recruited. Headache
and drug overuse were classified according to the
International Classification of Headache Disorders 3rd
Edition (beta version) [1].
Exclusion criteria were: foreign language as mother
tongue, pregnancy, secondary headaches, age < 18, non-
compliance. Secondary headaches were ruled out by
clinical examination, biochemical tests, and neuroimag-
ing studies, when indicated.
Participants gave written informed consent and the
study was carried out in accordance with the Declaration
of Helsinki; the study protocol was approved by the
Ethic Committee of the Local Health Service of Bologna,
Italy (protocol number: 07044).
Protocol
During the first visit (T0) patients who gave informed
consent and satisfied the inclusion criteria received a
headache diary, self-administered questionnaires (see
Additional file 1: Measures paragraph), and pharmaco-
logical therapy prescription. The pharmacological prophy-
laxis was chosen by the neurologist according to the
prophylactic therapy best suited to each patient, consider-
ing efficacy and side effects of previous treatments, co-
morbidity, and patient’s preferences. The neurologist also
informed patients about the risks of medication overuse,
asking to stop or reduce analgesic intake.
After 1 month (T1) psychophysiological measures were
recorded at rest. Headache diary and questionnaires were
administered again. At the end of the assessment patients
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were randomly assigned to the treatment group (Bfb
group) or to the control group (Control group).
Randomization codes were generated through com-
puter and inserted in numerical sequence into sealed
envelopes. Subjects were allocated in 1:1 ratio. The
psychologist knew patients’ allocation, while neurolo-
gists were blinded to it.
Patients in the Bfb group underwent 9 weekly sessions
of EMG biofeedback, whereas patients in the Control
group underwent 9 weekly sessions with a psychologist
in which they were interviewed about their previous
week’s headaches, their mood, and their analgesic intake.
In both groups patients were encouraged to stop or re-
duce analgesic overuse. Neurologists were blinded to
which group the patients belonged.
At the end of the treatment (T2) patients were evaluated
from the neurologist and from the psychologist (by psy-
chophysiological assessment). Headache diary and ques-
tionnaires were re-administered. The same procedure was
followed after 4 months from the end of the treatment
(T3). At 1 year from the end of the treatment (T4) pa-
tients were visited and evaluated by a neurologist.
Measures
Each time (T0, T1, T2, T3) patients were evaluated by
the following measures.
The Headache Diary is a monthly diary in which fre-
quency (number of days), intensity (from 1 to 3), and
duration (number of hours in a day) of headache attacks
were recorded along with the type and the amount of
analgesic intake.
PRSS (Pain Related Self Statements Scale) and PRCS
(Pain Related Control Scale) [30, 31] are two self-
administered questionnaires. The PRSS is an 18-item
questionnaire that assesses situation-specific aspects of
patients’ cognitive coping strategies for pain. Patients
have to choose on a Likert scale (0 to 5) how many
times they have thoughts such as “If I stay calm and
relax I feel better” or “I cannot tolerate this pain any-
more”. PRSS has two subscales: “Catastrophizing” and
“Active Coping”. The PRCS is a 15-item questionnaire
that measures general attitudes towards pain with state-
ments like “I myself can do something against my pain”
and it is divided into 2 subscales: ‘Helplessness’ and ‘Re-
sourcefulness’. Both questionnaires were demonstrated
to be valid and sensitive to change, and they are closely
related to pain intensity and interference from pain
experiences.
At T4 the neurologist evaluated the current headache
diagnosis and adherence to pharmacological treatment.
Physiological measures
The frontalis muscle electromyographic activity as a
measure of tension was recorded in baseline condition
and during the training. The EMG was recorded and fed
back to the subject by means of a Biofeedback Modular
System (Modulab series 800, SATEM, Rome, Italy).
Treatment
The EMG BFB treatment was carried out by a psycholo-
gist at Centro Gruber (Bologna), a service for the diag-
nosis and treatment of eating disorders and of anxiety
and psychosomatic disorders. The initial psychophysio-
logical assessment consisted of 2 sessions in which both
clinical data and psychophysiological recordings were
collected to assess the state of the patient before treat-
ment at baseline and under stress conditions. The 9
weekly sessions of frontalis muscle EMG BFB aimed to
reduce muscle tension. The treatment was divided into
three phases: a first acquisition phase, in which the feed-
back was always present (3 sessions), a second mainten-
ance phase, in which trials with and without feedback
were alternated (3 sessions), and a third exposure phase,
in which patients attempted to use the technique in
imagined situations subjectively perceived as stressful (3
sessions). In all phases patients did not were trained in
any relaxation technique, they were encouraged to find
muscle tension reduction strategies by themselves. The
treatment ended with a reassessment session. The pro-
cedure of the entire treatment (12 one hour weekly ses-
sions in all)was standardized and was the same for all
patients. The psychologist had to fill a checklist of the
status of adherence with the protocol.
Data analysis
The assumptions for the calculation of the sample
needed to test the primary end point were: a beta error
of 20 %, an alpha error of 5, 50 % of responders in the
experimental group and 10 % of responders in the
placebo group. Given these assumptions, at least 24 pa-
tients per group had to be recruited.
Descriptive statistics (means ± SD) were conducted on
the sample features. The sample was randomized into two
groups: Biofeedback group (Bfb Group) and Control group.
The normality of parameters distribution was checked
using Skewedness-Kurtosis. Chi-squared, Student’s T-test
and ANOVA repeated measures were performed to com-
pare data between groups at T1, T2 and T3. Bonferroni
correction for multiple comparisons was used. When ap-
propriate, post-hoc analyses were carried out. Data were
analyzed using the statistical software SPSS 19.0 (Statistical
Package for Social Science). Significance level was set at
two-tailed p < 0.05.
Results
Forty-seven of 72 patients with MOH consecutively re-
ferred to the Headache Center responded to the inclu-
sion criteria and accepted to participate. Three patients
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were excluded because at T1 they did not fulfill the
MOH diagnosis anymore, 10 participants dropped out
between T1 and T2 (6 in the Bfb group, 4 in the Control
group).
Analyses were conducted only in the 27 participants
who provided headache diary data for all measurement
periods and completed the study: 15 belonged to the Bfb
group, 12 belonged to Control group (Fig. 1).
Patients who did not complete the study did not differ
from other participants in: age (t = −.500, p = .620), sex (χ2
= 0.688, p = 0.41) educational level (χ2 = 0.719, p = 0.69)
and type of headache at onset (χ2 = 1.340, p = 0.51), but
they differed in age of chronification (t = 3.924, p < 0.001):
participants who dropped out of the study had suffered
from MOH for a longer period of time.
According to the original ICHD 3rd edition (beta ver-
sion), 24 of 27 subjects had a diagnosis of CM and
MOH and 3 of CTTH and MOH.
Table 1 shows patients’ demographic and headache
characteristics. Participants of the Bfb group and Con-
trol group did not differ in age (t = −1.060, p = 0.30), sex
(χ2 = 0.059, p = 0.81), educational level (χ2 = 0.617, p = 0.73),
type of headache at onset (χ2 = 1.739, p = 0.42), age of
chronification (t =−1.025, p = 0.31). Drugs used for pre-
ventive therapy were: antiepileptics (14 patients: 9 in Bfb
group and 5 in Control group), beta-blockers (5 patients: 2
in Bfb group and 3 in Control group), antidepressants (6
patients: 3 in Bfb group and 3 in Control group), Ca-
antagonists (2 patients in Control group), pizotifen (1 pa-
tient in Bfb group).
At the end of the treatment (T2) patients that
returned to episodic headache were respectively 10
(67 %) in the Bfb group and 2 (17 %) in the Control
group (χ2 = 6.750, p = 0.009); after 4 months (T3), 12
(80 %) in the Bfb group and 3 (25 %) in the Control
group (χ2 = 8.168, p = 0.004). After 1 year (T4), 7 patients
(47 %) in the Bfb group and 2 (17 %) in the Control
group (χ2 = 2.700, p = 0.10) remained episodic (Table 2).
Intention-to treat-analysis was performed on num-
ber of responders in the two groups. Including pa-
tients that did not complete the study as non
responders, the percentages of patients that return
episodic at the end of the treatment (T2) were re-
spectively the 37,5 % in the Bfb group, 10 % in the
Control Group (χ2 = 4.417, p = 0.036), at T3 44,44 %
in the Bfb group and 15 % in the Control Group (χ2
= 4.584, p = 0.032), at T4 25,92 % in the Bfb Group
and 10 % in the Control Group (χ2 = 1,88, p = 0.170).
Diary variables
Analyses were performed on the two groups (15 patients
of the Bfb group, 12 patients of the Control group)
(Table 3).
ANOVA repeated measures on attack frequency (num-
ber of attacks per month) yielded main effects for time
(p = 0.014) and group (p = 0.001) and a Group X Time
interaction effect (p = 0.001).
Post-hoc Fisher’s LSD comparisons showed a signifi-
cant reduction in frequency from T1 to T2 (p = 0.002)
and from T1 to T3 (p < 0.001) only in the Bfb group, no
differences in frequency were found in the Control
group from T1 to T2 and from T1 to T3. No differences
were found between the groups at T1.
Data about the intensity and duration of headache at-
tacks were not analyzed because they were indicated
only in 44 % of the diaries filled in by the patients.
Results about analgesic intake showed a main effect
for time (p < 0.025) and a Group X Time interaction
(p <0.012). Group effect was close to the significance
level, even if it did not reach it (p = 0.051).
Post-hoc Fisher’s LSD comparisons showed a significant
reduction in analgesic intake from T1 to T2 (p = 0.001)
and from T1 to T3 (p = 0.009) only in the Bfb group, no
differences in frequency were found in the Control group
from T1 to T2 and from T1 to T3. No differences were
found between the groups at T1.
Psychological measures
PRSS and PRCS results were analyzed in 25 patients (14 in
Bfb group, 11 in Control group) because their questionnaires
were invalid. In PRSS questionnaire ANOVA repeated mea-
sures was performed on the two scales: Catastrophizing and
Active Coping. In Catastrophizing, analysis showed a main
effect for time (F[1, 23] = 5.762; p = 0.006) and group
(F[1, 23] = 10.98; p = 0.003), but not for the interaction
Group x Time (F[1, 23] = .312; p = 0.73). On post-hoc
comparisons, a significant difference emerged between
the groups both in pre (p = 0.018) and post-training
(p = 0.006), at T3 the score decreased in both groups,
but only in the Bfb group the decrease was significant
(p = 0.019).
Fig. 1 Patients Flow
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In the scale Active Coping a time effect (F[1, 23] =
3.984; p = 0.044) and a Group X Time interaction (F[1,23]
= 4.499; p = 0.032) were detected. Post-hoc Fisher’s LSD
comparisons showed a significant increase of the scores
from T1 to T2 (p = 0.002) and from T1 to T3 (p = 0.047)
only in the Bfb group, no differences in Active Coping
were found in the Control group from T1 to T2 (p = 1.00)
and from T1 to T3 (p = 1.00). No differences were found
between the groups at T1 (p = 0.939).
In PRCS no main interaction effects were detected,
only in the subscale Helplessness a group effect was
found (F[1,23] = 8.772; p = 0.007). On post-hoc compari-
sons, the Bfb group had a lower score than the Control
group at T2 (p = 0.036) and at T3 (p = 0.004). Means and
Confidence intervals are available in the Additional files
1, 2 and 3.
EMG data
ANOVA repeated measures performed on frontalis
EMG in baseline condition at pre- (T1) and post-
treatment (T3) did not yield significant results (p = 0.52).
No differences were found overall between groups and
between the groups at T1 and at T3. No differences
were found overall between groups and between the
groups at T1 (Bfb Group = 2,47 ± 1,10 μV; Control
Group = 2,88 ± 1,25 μV) and at T3 (Bfb Group = 2,28 ±
0,60 μV; Control Group = 2,73 ± 1,17 μV).
Discussion
Our results indicate that at the end of treatment the Bfb
group had reduced the headache frequency and the
amount of drug intake and showed better active coping
with pain, compared with the Control group. These out-
comes were confirmed also after 4 months of follow-up.
These results are in line with previous studies, showing
that a combined treatment (biofeedback plus pharmaco-
logical therapy) for MOH is more effective than pharma-
cological therapy alone in reducing pain symptoms even
Table 1 Patients’ demographic and headache characteristics
Biofeedback Group Control Group Total
Gender
Male 2 2 4
Female 13 10 23
Age (mean ± sd) 40.13 ± 12.41 45.08 ± 11.60 42.33 ± 12.09
Educational Level
Primary/Secondary 2 3 5
High School 4 3 7
Graduate 9 6 15
Headache at onset
MWOA 11 10 21
MWA 2 0 2
TTH 2 2 4
Age of chronification (mean ± sd) 28.53 ± 9.96 32.25 ± 8.85 30.18 ± 9.49
Overused drugs
Triptans 7 5 12
NSAIDs/P 2 0 2
Combination-analgesics 1 2 3
Multiple drug classes 5 5 10
Drug prophylaxis
Monotherapy 9 7 16
Polytherapy 4 5 9
Abbreviations: MWOA migraine without aura, MWA migraine with aura, TTH tension type headache
Table 2 Frequencies and percentages of responders (patients
that returned episodic) at the end of treatment (T2), after
4 months (T3) and at 1 year (T4)
Responders Biofeedback group Control group
T2
n (%) 10 (67 %) 2 (17 %)
T3
n (%) 12 (80 %) 3 (25 %)
T4
n (%) 7 (47 %) 2 (17 %)
Rausa et al. The Journal of Headache and Pain  (2016) 17:87 Page 5 of 8
in the long run [24]. The combined treatment (biofeed-
back and pharmacological therapy) was compared with
pharmacological treatment after 10 days of drug inpatient
withdrawal. Headache frequency and analgesic intake im-
proved even after 3 years of follow-up. Further findings
have been obtained from the present study.
First, patients could modify analgesic intake with bio-
feedback independently of an analgesic-overuse struc-
tured withdrawal.
In recent literature the role of drug detoxification has
been debated [32–35]. Saper and Lake created a classifi-
cation system that can be useful in triaging these pa-
tients. Type 1 MOH refers to simpler cases of patients
who do not have behavioral impairments and do not
overuse opioids and barbiturates. Type 2 MOH patients
are complex and suffer from behavioral conditions or
chronically use opioids or barbiturates [36]. In our study
we did not differentiate between simple or complex
cases, in future research it could be useful to evaluate
such distinction in order to understand which type of
patients could benefit from biofeedback treatment. At
1 year of follow-up only 46 % of patients did not return
chronic, this result is in line with studies that indicated a
high level of relapse in MOH [37, 38] but it would have
been better supported if the distinction described above
had been used. Moreover, the duration of chronification
is one of the characteristics that differed in patients that
dropped out of the study. In future research this factor
should be taken into account in order to understand if
this type of patients need motivational intervention be-
fore starting biofeedback treatment or if they could not
benefit from this treatment at all.
Second, in our experimental design, patients of the
Control and Bfb group were followed up weekly and they
were encouraged to stop or reduce analgesic overuse, but
our control patients did not benefit from simple advice
and support [34], indicating that in order to help patients
in reducing drug intake it is necessary to give them differ-
ent strategies to cope with pain, and biofeedback could
help them achieve new self-regulatory strategies.
Third, patients in the Bfb group changed coping cogni-
tions after treatment, they reported using more active cop-
ing cognitions than the Control group. Active coping
cognitions included thoughts like “If I stay calm and relax,
things will be better” or “I can do something about my
pain” “I’ll manage” “or “I will cope with it”. Active coping
is opposite to pain catastrophizing, which generally refers
to exaggerated negative cognitive and affective reactions to
an expected or actual pain experience [39] and it is charac-
terized by magnification of the potential negative aspects
of pain, inability to disengage from thoughts about pain,
and a feeling of helplessness in coping with pain [40].
It has been stressed that pain catastrophizing may also
worsen the experience of pain through physiological and
neural pathways by enhancing it via differential patterns of
brain activation [41] and by modulating the analgesic effects
of medications affecting the endogenous opioid system [42,
43]. Our data allowed us to argue that the acquisition of
self-regulation strategies could probably help patients to
promote active behaviors and to activate different problem
solving strategies. The meta-analysis of Nestoriuc supports
this hypothesis, showing that frequency of migraine attacks
and perceived self-efficacy had the strongest improvements
after the treatment [16].
Nonetheless, modifications of coping cognitions in the
biofeedback treatment of MOH needs more evaluations
to understand the role of biofeedback in changing
coping skills.
Fourth, these results were independent of psychophysio-
logical modification, in fact no differences were found in
EMG frontalis muscle level at rest after treatment. It could
be hypothesized that if sensors had been placed differently
(e.g., on the trapezius muscle or on the site most associ-
ated with pain), that would have led to more specific
EMG results. Moreover, given the effects of BFB training
on patients’ coping strategies it could be speculated that
BFB acted as a general arousal control strategy [44].
Therefore, in future studies, EMG feedback should be
compared with skin conductance or thermal feedback,
which more closely reflect the subject’s arousal.
Table 3 ANOVA results
Clinical index Biofeedback group Control group Group effect Time effect Interaction group
X time effect
T1 T2 T3 T1 T2 T3
M(CI95%) M(CI95%) M(CI95%) M(CI95%) M(CI95%) M(CI95%)
Frequency
(days/month)
19.93
(17.49;
22.37)
13.93
(10.52;
17.34)
13.00
(9.63;
16.37)
22.08
(19.36;
24.81)
24.25
(20.43;28.06)
22.33
(18.56;
26.10)
**F[1,25] =
14.11;
*F[1,25] =
5.44;
**F[1,25] = 9.62;
p = 0.001 p = 0.014 p = 0.001
Analgesic intake
(number tot/
month)
21.27
(13.68;
28.85)
11.93
(4.31; 19.53)
12.40
(2.83;
21.97)
26,62
(18.14;
35.11)
27.04
(18.54;
35.54)
21.17
(16.47;
37.86)
F[1,25] = 4.192; *F[1,25] =
4.52;
*F[1,25] = 5.561
p = 0.051 p = 0.025 p = 0.012
Abbreviations: M mean, CI 95 % confidence interval 95 %
*p<0.05 **p<0.01
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The most important limit of this study is the number of
participants that concluded it, as the sample size deter-
mined by the calculation of the sample had not been
reached. It was difficult to recruit patients and, in particu-
lar, to obtain all data for two main reasons: the protocol’s
length and the poor compliance that characterizes this
kind of patients [11]. For this reason we considered it a
pilot study.
Another limit was that at 1 year of follow-up we could
not analyze frequency and intensity of headache attacks
due to missing data. Also psychological measures could
not be collected. Moreover, at 1 year the number of
patients that had returned to episodic headache was
reduced in the Bfb group and the difference with the
control group did not remain significant.
After 1 year patients generally referred that they were
not practicing self-regulatory strategies anymore. In
future biofeedback protocols it could be useful to plan
“recall sessions” at 4, 6, and 9 months and at 1 year from
the end of treatment in order to prevent both relapse
and missing data.
The sample of the present study included also patients
with CTTH, however it was not possible to evaluate
differences in the response to treatment according to
diagnosis differences, due to the small number of the
CTTH sample.
Conclusions
The results of our study encourage the use of biofeedback
in combination with pharmacotherapy in order to stop or
reduce analgesic drug overuse. Biofeedback added to trad-
itional pharmacological therapy in the treatment of MOH
is a promising approach for reducing the frequency of
analgesic intake. Our study also stressed how complex the
study of MOH patients is, suggesting that a multicenter
randomized control trial could be useful to establish
biofeedback efficacy in this kind of patients.
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